Ms. Hoyle of Oregon (for herself, Mr. Doggett, Ms. Stansbury, Mr. Takano, Ms. Norton, Ms. Tlaib, Ms. Jayapal, and Mr. Casar) introduced the following bill; which was referred to the Committee on Energy and Commerce
To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes.
Citations are generated automatically from bibliographic data
as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. House. Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026. H.R. 10094. 119th
Cong., 2nd
sess., Introduced in House August 13, 2026. https://www.govinfo.gov/app/details/BILLS-119hr10094ih.
APA
Congress, House of Representatives (2026, August 13). Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 (H.R. 10094 (IH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-119hr10094ih.
MLA
United States, Congress, House of Representatives. Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-119hr10094ih. 119th Congress, H.R. 10094, Introduced in House 13 Aug. 2026.
Bluebook
H.R.10094 - 119th Congress (2025-2026): Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026, H.R.10094, 119th Cong. (2026), https://www.govinfo.gov/app/details/BILLS-119hr10094ih.
